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CD4+ T follicular helper cells (TFH) were assessed in adult patients with common variable immune deficiency (CVID) classified
according to the presence of granulomatous disease (GD), autoimmunity (AI), or both GD and AI (Group I) or the absence of AI
and GD (Group II). TFH lymphocytes were characterized by expression of CXCR5 and PD-1. TFH were higher (in both absolute
number and percentage) in Group I than in Group II CVID patients and normal controls (N). Within CXCR5+CD4+ T cells, the
percentage of PD-1 (+) was higher and that of CCR7 (+) was lower in Group I than in Group II and N.The percentages of Treg and
TFH reg were similar in both CVID groups and in N. TFH responded to stimulation increasing the expression of the costimulatory
molecules CD40L and ICOS as did N. After submitogenic PHA+IL-2 stimulation, intracellular expression of TFH cytokines (IL-10,
IL-21) was higher than N in Group I, and IL-4 was higher than N in Group II.These results suggest that TFH are functional in CVID
and highlight the association of increased circulating TFH with AI and GD manifestations.
1. Introduction
Common variable immunodeficiency (CVID) comprises a
heterogeneous group of diseases characterized by abnormal
antibody production [1]. It is the most commonly diagnosed
primary immunodeficiency, with an incidence of 1/10 000
to 1/50 000. It affects both sexes equally and the clinical
manifestations may begin at any age [2–4]. Over 90% of
the patients present with recurrent acute and sometimes
chronic bacterial infectionsmainly of the respiratory and gas-
trointestinal tracts. Another feature of these patients is their
major susceptibility for autoimmunity (AI) manifestations,
granulomatous diseases (GD), and cancer [5–10]. Diagnosis
of CVID is based on a significant decrease of IgG (at least
two standard deviations below the mean for age) associated
with a decrease of IgA and/or IgM isotypes, in patients older
than 4 years of age and absence of isohemagglutinins and/or
poor response to polysaccharide vaccines, with other defined
causes of hypogammaglobulinemia excluded [2–4, 11].
In most cases the etiology of CVID is not known.
In a small percentage of patients, most families stranded,
a few genetic defects have been described. These include
mutations in genes coding for the inducible costimulator
(ICOS) [12], CD19 [13, 14], CD20 [15], CD8 [16], and the B
cell-activating factor receptor (BAFF-R) [17]. Eight to 10%
of the patients carry mutations in the gene for the B cell
receptor transmembrane activator and calcium-modulating
cyclophilin ligand interactor (TACI). Similar mutations are
found in unaffected relatives and normal controls, suggesting
association but not causality [10, 18–23].
The process of acquiring an adequate antibody immune
response is complex and involves specialized groups of T
lymphocytes that interact with B lymphocytes in a tightly
regulated way in the secondary lymphoid organs. This ulti-
mately results in the generation of different immunoglobulin
isotypes, memory effector, and regulatory cells. Failure at any
of the stages of the process may lead to humoral immuno-
deficiency.
T follicular helper cells (TFH) have a central role in the
generation of the germinal center reaction (GC) which is
necessary for the correct maturation of the humoral immune
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response. Their absence or functional impairment generates
defects in the assembly of B cell memory that lead to
hypogammaglobulinemia. Most studies concerning the role
of this T helper subset have been done in animal models,
but in humans there is evidence that a group of CD4+ T
lymphocytes characterized by the presence of the chemokine
receptor CXCR5 reflects TFH present at the lymph nodes
[24–26]. Programmed-death 1 (PD-1) is highly expressed
in germinal center TFH and its expression is induced after
activation in CD4 and CD8 cells [27–29]. The inhibitory
role of the PD-1/PD-ligand (PDL-1 or PDL-2) axis has been
defined in relation to theT cellmediated response to antigens,
but its role in the regulation of the B cell responses is
less clear. While some studies report attenuated antibody
responses where the PD-1/PDL-1 and PDL-2 interactions
are prevented [30], others observed heightened immune
responses in coincidence with increased TFH numbers [31].
Circulating TFH are phenotypically and functionally het-
erogeneous. A subgroup of TFH with central memory/resting
profile expressing chemokine receptor 7 (CCR7) predomi-
nates in normal individuals, while in patients with autoim-
mune conditions, TFH with high expression of programmed-
death 1 (PD-1) and low CCR7 are more abundant [32]. In
addition, a subgroup of TFH expressing both CXCR5 and
FoxP3 (TFH reg) that may suppress TFH activity has been
described [33]. Antibody deficiency and immune dysregu-
lation in CVID could be related to absence or inefficient
function of TFH, to increased TFH reg action leading to
downregulation of T/B cell cooperation for the synthesis of
antibodies, or to interference with TFH action due to other
regulatory lymphocytes as CD8+ regulatory cells [34]. Based
on these observations we decided to study the characteristics
and function of TFH in peripheral blood of adult CVID
patients divided into two clinical phenotypes according
to the presence or absence of autoimmunity (AI) and/or
granulomatous disease (GD).
2. Material and Methods
2.1. Subjects. We reviewed the clinical and epidemiological
data of our cohort of twenty-one adult patients with CVID.
The diagnosis of CVID was made according to standard
criteria [2, 3], and all subjects were onmonthly immunoglob-
ulin replacement therapy. Based on patients’ clinical records,
we analyzed the age at onset of infectious symptoms, age
at diagnosis, age at the time of the study, length of follow-
up from CVID diagnosis to time of the study, and clinical
manifestations. Patients were divided into two categories:
Group I (𝑛 = 8), patients with AI, GD, or both, and Group
II (𝑛 = 13), patients without these clinical manifestations.
Blood samples were drawn before the infusion of
immunoglobulin. All studies were performed blinded to the
clinical manifestations of the immunodeficiency. Controls
(𝑛 = 19) were age related normal blood donors (N). This
study was approved by the Ethics Committee of Academia
Nacional de Medicina. All donors gave informed consent.
2.2. PBMC Isolation and Culture. Peripheral blood samples
from all subjects were collected on heparin. PBMC were
obtained by Ficoll-Hypaque (FH) centrifugation and sus-
pended to 1 × 106/mL in RPMI tissue culture medium
containing 10% fetal calf serum (GIBCO,Grand Island,USA),
streptomycin, and penicillin (RPMI-FCS). PBMC cultures
were carried out in round bottom 5mL polystyrene tubes
(Falcon) containing 2 × 106 PBMC that were suspended in
2 mL RPMI-FCS [35].
2.3. Cell Surface Phenotype of Mononuclear Cells from CVID
Patients and N Controls. For assay of the different types of
lymphocytes, flow cytometry techniques with a three-color
assay were used. Aliquots of 100 𝜇L heparinized peripheral
blood were incubated with monoclonal antibodies and then
were lysed using FACS Lysing solution (Becton Dickinson,
San Jose, CA, USA) following the manufacturer’s instruc-
tions. Analysis of surface markers was performed on a
FACScan cytometer (Becton Dickinson, San Jose, CA, USA)
and analyzed with FCS Express software. Lymphocytes were
selected according to size (FSC) and side (SSC) scatter pro-
files. PBMCwere also processed both before and after cell cul-
ture. Fluorescein isothiocyanate (FITC), phycoerythrin (PE),
Alexa 488, or peridinin chlorophyll protein (PerCP) anti-
human labelled monoclonal antibodies were used according
to the manufacturers’ instructions. Anti-CD4 (clone RPA-
T4), CD25 (clone M-A251), CD45RO (clone UCHL1), CXC-
chemokine receptors, 5 (CXCR5) (CD185, clone RF8B2) and
7 (CCR7, Clone 3D12), CD19 (clone HIB19), CD27 (clone
M-T271), inducible T cell costimulator (ICOS) (CD278,
clone DX29), CD40 ligand (CD40L) (CD154, clone TRAP1),
and programmed-death 1 (PD-1) (CD279, clone MIH4)
antibodies were purchased from BD Pharmingen, BD, and
eBioscience (San Diego, CA, USA). Absolute numbers of the
different lymphocytes were calculated taking into account the
white cell count and the percentage of lymphocytes in May-
Grünwald-Giemsa stained blood smears.
The phenotype of viable PBMC fromCVID andNdonors
was analyzed before and after 2 or 7 days of PHA+IL-2
stimulated culture (performed as detailed below for the assay
of cytokines). Lymphocyte viability was calculated taking into
account the proportion of live lymphocytes in the SSC/FSC
dot plots. Appropriate isotype controls were used to define
the positive populations.
2.4. FoxP3+CD25+ T Cells (Treg) and FoxP3+CXCR5+ T
Cells (T
𝐹𝐻
reg). For Treg and TFH reg determination, PBMC
were stained with PerCP anti-CD4 and FITC anti-CD25
or PerCP anti-CD4 and Alexa 488 anti-CXCR5. Then they
were fixed and permeabilized with Fix and Perm (Caltag
Laboratories, Burlingame, California, USA) according to
the manufacturer’s instructions. After permeabilization they
were reactedwith PE anti-FoxP3 (clone PCH101, eBioScience,
San Diego, CA, USA).
2.5. Costimulatory Molecules (CD40L and ICOS) and Intra-
cellular Il-10, IL-21, and IL-4 in CVID and N. PBMC
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Table 1: Clinical and epidemiological data of Group I patients.





1 F 65 31 41 24 Larynx, bowel, conjuntiva, skin Hypothyroidism
2 M 36 1 13 23 LIP, LN AHA
3 F 21 16 17 4 0 ITP, AHA
4 M 69 50 66 3 Lung, bowel ITP
5 F 69 ND 66 3 LIP 0
6 F 36 ND 20 16 0 E N
7 M 30 ND 14 16 Lung, LN ALOP
8 F 59 25 43 16 0 AHA, N
LN: lymph node; LIP: Lymphocytic interstitial pneumonia. LIP diagnoses were made by pathological examination in patients #1, #2 and #7. LIP in patient #4
was established by CAT scan. AHA: autoimmune hemolytic anemia; ALOP: alopecia aereata; ITP: immune thrombocytopenia; EN: erythema nodosum, N:
autoimmune neutropenia.
(106/mL) were stimulated with 2.5𝜇g/mL phytohemagglu-
tinin (PHA-P, Sigma, L1668, St. Louis, MO, USA) and
5UI/mL interleukin-2 (IL-2, Peprotech, New Jersey, USA)
and cultured at 37∘C in the CO
2
incubator for 2 days for
costimulatory molecules and for 7 days for intracellular
cytokines. The time and concentration of PHA and IL-2
were selected on the basis of previous studies [36]. IL-2 was
replenished after 5 days of culture. Controls consisted of
PBMC cultures performed in the absence of PHA and IL-2.
For costimulatorymolecules, PBMCwere stainedwith PerCP
anti-CD4, Alexa 488 anti-CXCR5, and either PE anti-CD40L
or PE anti-ICOS. For intracellular cytokines, twelve hours
before harvesting the cell pellets, these were resuspended in
RPMI-FCS (106/mL) and 10 𝜇L of 2 𝜇M monensin solution
(BD Pharmingen, San Diego, CA, USA) was added to the
cell suspensions. After washing, the cells were stained with
CD4, CXCR5 monoclonal antibodies for 20 minutes at room
temperature and then fixed and permeabilized with the
Fix and Perm (Caltag Laboratories, Burlingame, California,
USA). Cells were finally stained with anti-IL-10 (clone JES3-
9D7), anti-IL-21 (clone 3A3-N2.1), or anti-IL-4 (clone 8D4-8)
antibodies (BD Pharmingen, San Diego, CA, USA) and the
appropriate isotype controls for 45 minutes at 4∘C, washed
again, and the percentage of intracellular IL-10+, IL-21+, or
IL-4+ CD4+ lymphocytes as well as that of CD4 lymphocytes
that coexpressed CXCR5 and IL-10+, IL-21+, or IL-4+ was
determined.
2.6. Statistical Analysis. Graphical presentation and statis-
tical analysis of the data were performed using Graph-
Pad Prism 4.0 (GraphPad Software, San Diego, CA, USA).
Comparisons between groups were analyzed by a one-way
ANOVA and a nonparametric Mann-Whitney test. Corre-
lations between samples were calculated using the linear
regression model. 𝑃 values of less than 0.05 were considered
significant.
3. Results
3.1. CVID Patients. We analyzed data on 11 male and 10
female CVID patients; the mean age of patients at the time
of the study was 49.9 ± 15.8 years (range 21 to 73), median
38.5. The age at onset of disease was available for 15 patients,
one patient did not have infections, and mean age was 19.4 ±
15.2 years (range 1 to 50), median 19. Mean age at diagnosis
was 35.4 ± 18.2 years (range 13 to 70), median was 31.5 years,
and mean follow-up duration was 10.6 ± 7.8 years (range
1 to 24), median 10.5. All patients were on gammaglobulin
replacement therapy since diagnosis.
Patients were divided into two categories, Group I, eight
patients, and Group II, 13. The clinical and epidemiological
data of Group I patients are shown in Table 1. Patients 4 and
5 had AI disease manifestations 13 and 33 years, respectively,
before the onset of infectious symptoms. With the exception
of patient 1 that was studied under steroid and infliximab
treatment [37], none of the patients in Group I received
systemic steroids, standard immunosuppressive therapies, or
biologic agents at the time of the study.
3.2. Absolute Values of T and B Lymphocytes in CVID and N.
The total number of lymphocytes, CD4+T cells, and TFH cells
(CXCR5+CD4+) was measured in peripheral blood from
CVID patients, right before iv immunoglobulin replacement.
As shown in Figure 1, the number of CD4+ lymphocytes was
not significantly different in both CVID groups compared to
N, but TFH cells were elevated, especially in Group I patients
(Figure 1(a)).
In Group I patients the absolute number of CD19+ cells
correlated with that of TFH cells suggesting a link in the
regulation of these two cell populations (Figure 1(b)). There
was no significant correlation between CD19+ cells and TFH
in Group II andN. A similar analysis was performed between
the absolute number of CD27+CD19+ and those of TFH cells.
We found significant correlation only in Group I of patients.
In 2/8 Group I patients and in 6/13 of Group II patients,
the percentage of CD19+ B lymphocytes (1.6 to 4.71%) was
below normal (N% CD19+, mean + SD: 9.93 + 3.21, 𝑛 = 15).







reg in CVID andN. Because CD4 lymphocytes
provide essential help for the maturation of B cell memory,
we further analyzed the expression of markers associated
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Figure 1: TFH and B lymphocyte absolute values in CVID andN. (a) Absolute lymphocyte values (cells/mm
3) were calculated in CVIDGroup
I, 𝑛 = 8 (I), and Group II, 𝑛 = 13 (II), patients and control donors (N), 𝑛 = 19. Peripheral blood was stained with monoclonal antibodies
and absolute values of viable CD4+ T lymphocytes and CD4+ T cells coexpressing CXCR5 (TFH) were calculated after analysis on a FACScan
Becton Dickinson flow cytometer. (b) A comparison between peripheral blood viable B lymphocytes (CD19+ cells), memory B lymphocytes
(CD27+CD19+ cells), and TFH values (CXCR5+CD4+ cells) was done in CVID Group I, Group II, and N controls. Lineal regression analysis
was consigned in the graphs. Only in Group I was the correlation statistically significant.
with follicular helper T cells (CXCR5 and PD-1) in CD4
lymphocytes. The results shown in Figure 2 demonstrate that
the percentage of CXCR5+CD4+ T cells was higher in Group
I CVID patients when compared to those of Group II and N.
Regarding Group II CVID patients, there were no significant
differenceswhen compared toN.Concerning coexpression of
PD-1 and CXCR5, the highest values were observed in CVID
patients with a GD and/or AI disease phenotype (Group I).
In some patients the studies could be repeated after 12–
24 months and the CXCR5+PD-1+ percentages in the CD4
region remained high (patient #CM initial value: 23.28%;
after 24months: 25.91%; after 26months: 25.32%; patient #PV
initial value: 15.5%; after 12 months: 18.39%; after 14 months:
16.38%).
Because low CCR7 and high PD-1 expression have been
observed in circulating TFH from patients with autoimmune


















































































































































































Figure 2: Percentage of TFH (CXCR5+CD4+ T cells) and of TFH coexpressing PD-1 in CVID and N. (a) The percentage of CD4+ T cells and
CD4+ T coexpressing CXCR5 or CXCR5+PD-1+ was assayed for CVID patient Groups I (𝑛 = 7) and II (𝑛 = 10) and N (𝑛 = 12). Statistical
differences are consigned in the graph. (b) An example of cytometry analysis of two different Group I and Group II CVID patients and two
different N controls.
conditions, we examined the TFH subsets considering the
level of expression of these molecules on the surface of
CXCR5+CD4+ T cells from CVID patients and N controls.
The results shown in Figure 3 demonstrate that high PD-1 and
low CCR7 expression were the rule in Group I compared to
Group II and N. PD-1 was also higher than N in Group II but
CCR7 values did not differ from those of N.
The percentages of Treg (CD25+ Foxp3+/CD4) and TFH
reg (CXCR5+ Foxp3+/CD4) within the CD4+ T lymphocyte
region were similar in both CVID groups and in N (mean ±























































Figure 3: CCR7 and PD-1 expression in TFH of CVID patients.The percentage of CCR7+ cells within the CXCR5+CD4+T lymphocyte region
was calculated for CVID Group I and Group II patients and N (% CXCR5+CCR7+/CXCR5+) (a). Likewise, the percentage of PD-1+ cells in
the CXCR5+CD4+ T lymphocyte region was determined (CXCR5+PD-1+/CXCR5+) (b). Statistical differences are consigned in the graph.
SD, Group I, Treg: 4.42 ± 1.61%, TFH reg: 3.54 ± 1.38%; Group
II, Treg: 4.88 ± 4.61%, TFH reg: 3.21 ± 2.87%; N, Treg: 4.00 ±
2.16%, TFH reg: 2.30 ± 1.83%).
3.4. Upregulation of Costimulatory Molecules CD40L and
ICOS in CVID andN. Defects in the expression of costimula-
tory molecules on CD4 lymphocytes could underlie the lack
of an adequate humoral response. Therefore we examined
CD40L and ICOS expression on CD4 T lymphocytes and
CXCR5+CD4+ T lymphocytes after 2 days of culture either
nonstimulated (medium) or with PHA+IL-2 stimulation
(PHA+IL-2). After T cell stimulation, expression of both
CD40L and ICOS could be induced in CD4 cells and in
CXCR5+CD4+ T lymphocytes from CVID patients to a
similar extent to N (Table 2).
3.5. IL-10, IL-21, and IL-4 Induction by T Cell Stimuli in CVID
andN. Although other subtypes of T helper lymphocytes can
synthesize these cytokines, humanTFH produce abundant IL-
21 and IL-10 upon stimulation. IL-4 is also a CD4-derived
cytokine involved in the process of antibody generation and
it can be produced by Th2 CD4 lymphocytes and by the Th2
subset of TFH [24]. In order to assess the ability of CD4 T cells
to produce these cytokines, PBMC were stimulated with a
submitogenic dose of PHAand IL-2.Thepercentage ofCD4T
cells with intracellular IL-10, IL-21, or IL-4 was recorded.The
percentage of IL-10+ and IL-21+CD4+Tcellswas higher than
N inCVIDGroup I andGroup II after PHA stimulationwhile
IL-4+ CD4+ T cells were not different to N in both CVID
groups. When considering cytokine (IL-10, IL-21, and IL-4)
expression by CD4+CXCR5+ T cells (TFH), it was similar in
both groups of CVID to that of N. However, when cytokine
expression (IL-10 and IL-21) was analyzed in CD4+ T cells
that did not express CXCR5, it was significantly higher (𝑝 <
0.029) in bothCVIDgroups than inN (Figures 4(a) and 4(b)).
IL-4 expression was higher than N (𝑝 = 0.036) in CXCR5−
CD4+ T cells (Figure 4(c)) in Group II patients.
4. Discussion
It is difficult to determine the immunopathogenic importance
and/or predictive value of different laboratory findings in
relation to clinical manifestations in adult CVID. Attempts
to correlate clinical observations with laboratory data has
led to different classifications that take into account serum
immunoglobulin levels, flow cytometry characteristics of
CVIDB lymphocytes, or B lymphocyte function [38]. Pheno-
typing of B cell subpopulations has confirmed the reduction
of switched memory B cells (IgM-IgD-CD27+CD19+) in
association with splenomegaly or granulomatous disease
[38]. Changes in the proportion of other subgroups of B
lymphocytes have also been described in CVID [39–41].
We have now studied a series of adult CVID patients,
trying to correlate clinical findings with some characteristics
of the peripheral blood T lymphocyte phenotype. Patients
were divided in two groups: those who had evidence of AI
disease or GD (Group I) and those who did not (Group II).
Because TFH are important for the setup of a correct
antibody response, we have focused on this helper T cell
subpopulation in relation to the occurrence of immune
dysregulation associated with GD or AI disease. Interestingly,
we observed that the number of CXCR5+CD4+ T cells was
significantly related to the number of CD19+ B lymphocytes,
in Group I patients (with a similar tendency in N), suggesting
that there may be a link in the regulation of the number of
these lymphocytes.
Our results clearly show that the TFH population was
expanded in both groups of CVID patients, but CXCR5 and
PD-1 coexpression was higher in Group I than in Group
II and N. PD-1 is a potent inhibitory receptor important
for T cell tolerance and it has been associated with CD8
T cell exhaustion during chronic viral infection [7, 28, 42].
A subgroup of TFH defined by high PD-1 and low CCR7
expression has been demonstrated in patients with autoim-
mune conditions [32]. These cells seem to be the counterpart
of active effector CD4 T cells within the TFH compartment
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Table 2: Expression of costimulatory molecules (CD40L and ICOS) in PHA+IL-2 stimulated PBMC from CVID patients and N.
Costimulatory molecules expression in CD4+ lymphocytes (%, mean ± SE)
CD40L+ CXCR5+CD40L+ ICOS CXCR5+ICOS+
Group I (𝑛 = 4)
Medium 1.8 ± 2 1.7 ± 1.2 3.0 ± 0.2 2.2 ± 1.7
PHA+IL-2 11.0 ± 3.7 9.4 ± 3.5 24.4 ± 8.2 17.0 ± 5.3
Group II (𝑛 = 4)
Medium 2.4 ± 2 1.9 ± 1.1 4.3 ± 1.8 3.0 ± 1.7
PHA+IL-2 11.5 ± 4.1 10.3 ± 4.2 22.8 ± 9.0 15.6 ± 6.5
Normals (𝑛 = 7)
Medium 2.3 ± 1.5 2.0 ± 1.3 2.8 ± 3.2 1.8 ± 0.9
PHA+IL-2 7.3 ± 1.5 6.4 ± 1.5 16.3 ± 1.8 7.2 ± 1.1
PBMC were stimulated with 2.5 𝜇g/mL phytohemmagglutinin and 5UI/mL interleukin-2 for 2 days and then were stained with anti-CD4, anti-CXCR5 and
either anti-CD40L or anti-ICOS. The percentage of CD4+ cells that express CD40L, CXCR5 plus CD40L, ICOS and CXCR5 plus ICOS is consigned. No
significant differences were observed between both CVID groups and Normals.
and contrast with central memory/resting TFH having high
CCR7 expression and lower PD-1 that are present in higher
numbers inN. In our series, TFH exhibiting highPD-1 and low
CCR7 were also more prominent in Group I than in Group
II and N. Nevertheless, it is interesting to note that TFH from
Group II patients without AI or GD had also lower CCR7 and
higher PD-1 expression than N. Long term follow-up of these
patients may give an insight into the relationship of TFH and
development of AI or GD in CVID.
Recently, the regulatory role of TFH lymphocytes bearing
the Treg transcription factor FoxP3 and CXCR5 (TFH reg) in
the generation of humoral immunity has been emphasized
[43]. It was found that PD-1/PD-ligand 1 (PDL-1) interactions
affected the outcome of T/B cooperation. PD-1 deficient
mice had more TFH reg than wild type mice and these PD-
1 deficient TFH reg had enhanced ability to suppress TFH
function [43]. Apparently, overexpression of FoxP3+ CD4+ T
cells (either Treg or TFH reg) was not the case in CVID, since
neither Treg nor TFH reg values differed from those of N in
both CVID groups.
In addition to detailed studies on B lymphocyte pheno-
type and differentiation in CVID patients, the function of
both CD4+ and CD8+ T lymphocytes has been thoroughly
studied in CVID. A defect in the integration of activating
signals derived from the TCR and costimulatorymolecules in
CD4 and CD8 T lymphocytes in CVID patients was demon-
strated [44]. Furthermore, it was shown that the proliferative
response of purified CD4 and CD8 T lymphocytes to recall
antigens and superantigens was impaired due to a defect in
the early phase of T cell receptor-mediated T cell activation
[45]. Antigen presentation by CVID monocytes or B lym-
phocytes was unaffected in CVID [46]. Our studies have
been focused on the action of a nonmitogenic dose of PHA
on TFH in culture. There are important differences in this
experimental procedure and the ones reported before. We
did not evaluate the proliferative response of PBMC and we
did not work with purified cell populations (CD4 or CD8) as
did the previous studies. In spite of their increased numbers,
the function of TFH could have been impaired in CVID. Our
results demonstrate that TFH cells (in the presence of the
monocytes and B lymphocytes that coexist in PBMC) are able
to upregulate the costimulatory molecules CD40L and ICOS
and can respond in vitro by producing the cytokines involved
in T-B cooperation to the same extent in Group I and Group
II patients as in N.This does not imply that upon physiologic
TCR stimulation this will be occurring in vivo. Intracellular
synthesis of IL-10 and IL-21 (cytokine markers of TFH cells)
as well as that of IL-4 was similar to that of N in PHA-
stimulated CVID CD4+CXCR5+ T lymphocytes. Notably,
intracellular expression of IL-10, IL-21, and IL-4 was also
higher than N in PHA-stimulated CXCR5-negative CD4+ T
cells from CVID patients. In this regard, an important role
of IL-21 (either from TFH or from other cell sources) as a
player in the differentiation ofTh17 cells that are important in
autoimmunity has been recently proposed [47]. It is possible
that an IL-21-stimulatedTh17 response could play a role in the
generation of AI or EG in CVID patients. Because TFH com-
prise a heterogeneous group of cells, increased circulating
CXCR5+CD4+ T lymphocytes might not reflect their ability
to cooperate with antibody production. Th2TFH are required
for adequate antibody synthesis, while Th1TFH are not [24].
The fact that after stimulation with PHA CXCR5+CD4+ T
cells from CVID patients produced IL-4 in addition to IL-21
and IL-10 indicates that lack of Th2TFH was not the cause of
the immunologic defect in this case.
High TFH in circulation has also been reported in some
autoimmune conditions [48] and this is interesting in relation
to the increased occurrence of autoimmune phenomena in
CVID. Indeed, in juvenile dermatomyositis (JDM), immune
dysregulation leads to skewing of blood CXCR5+ Th (TFH)
subsets towards Th2 and Th17TFH [24], while in JDM and
other autoimmune conditions as systemic lupus erythemato-
sus (SLE) or Sjogren’s disease, increased levels of functional
CXCR5+CD4+ T cells lead to hypergammaglobulinemia
and autoantibody synthesis [49–51] in CVID hypogamma-
globulinemia or selected immunoglobulin deficiency occurs,
probably as a result of impaired B cell maturation [52]. On the
other hand, repeated infections or continuous activation of
the inflammatory response [53] could also determine the TFH
increase, since circulating TFH with an active effector profile











































































Figure 4: Intracellular cytokines after PHA+IL-2 stimulation of PBMC in CVID and N. The percentage of intracellular cytokines ((a) IL-10,
(b) IL-21, and (c) IL-4) in permeabilized CD4+ T cells (CXCR5+ and CXCR5−) was determined after 7 days of PHA+IL-2 stimulation in
CVID Group I (𝑛 = 4), Group II (𝑛 = 4), and N (𝑛 = 6). Statistical differences are consigned in the graph. White bars represent unstimulated
controls.
(high PD-1, low CCR7) were highest in patients with GD, AI,
or both GD and AI manifestations.
5. Conclusions
Our results demonstrate that circulating TFH are higher than
normal in adult CVID patients. TFH were able to respond
to stimulation upregulating costimulatory molecules and
providing the appropriate B helping cytokines. This suggests
that intrinsic functional TFH defects are not the primary
cause of CVID. Moreover, increased levels of circulating TFH
highlight the relationship of CVID with other autoimmune
diseases.
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